A single-arm, single-center, prospective real-world study of Tislelizumab in the treatment of patients with advanced metastatic or unresectable renal clear cell carcinoma

The preliminary efficacy and safety analysis of Tislelizumab in patients with advanced metastatic or unresectable renal clear cell carcinoma

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100047036

Enrollment

Unknown

Registered

2021-06-07

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced renal clear cell carcinoma

Interventions

Tilelizumab group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Sign informed consent and voluntarily join this research; 2. Tissue/cytopathological examination confirmed that it was advanced renal clear cell carcinoma; 3. Aged >= 18 years; 4. The investigator determines that the patient can receive tislelizumab as a single agent or combination therapy.

Exclusion criteria

Exclusion criteria: 1. Patients who have received other immunological drugs or therapies at the same time; 2. Patients who are participating in other interventional studies; 3. Patients with other malignant tumors at the same time; 4. Pregnant and lactating women; 5. The researcher believes that the patient is not suitable to participate in any other situations in this research.

Design outcomes

Primary

Measure	Time frame
Objective response rate;	—

Secondary

Measure	Time frame
Disease control rate;Progression Free Survival;Duration of relief;	—

Countries

China

Contacts

Public ContactGou Xin

The First Affiliated Hospital of Chongqing Medical University

gouxincq@163.com+86 13883369433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026